ArkBio Launches Phase II Study for Innovative RSV Preventative Antibody AK0610 ArkBio has initiated a Phase II clinical trial for AK0610, a monoclonal antibody developed to prevent respiratory syncytial virus (RSV) infections in infants in China.

ArkBio Launches Phase II Study for Innovative RSV Preventative Antibody AK0610 #China #Shanghai #RSV #ArkBio #AK0610